Analyst Raises Eli Lilly (LLY) Price Target by $52 Following Q1 Report

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best US Stocks to Invest in According to Billionaires.

Analyst Raises Eli Lilly (LLY) Price Target by $52 Following Q1 Report

Eli Lilly and Company (NYSE:LLY) discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

On May 8, Guggenheim analyst Seamus Fernandez boosted the firm’s price target on Eli Lilly and Company (NYSE:LLY) from $1,183 to $1,235, while maintaining a ‘Buy’ rating on the shares. The revised target, which indicates an upside of almost 28% from the current price level, comes after the analyst firm updated its model following Eli Lilly’s Q1 results.

Eli Lilly and Company (NYSE:LLY) reported strong results for its first quarter on April 30, with the firm beating expectations in both profits and revenue. The company’s revenue grew by 56% YoY, and adjusted EPS surged by a massive 156% YoY, as the soaring demand for its GLP-1 weight-loss and diabetes drugs helped offset lower prices across the US ‌and international markets.

Notably, Eli Lilly and Company (NYSE:LLY) hiked ​its profit and revenue forecasts for full-year 2026. The company now expects its revenue to range between $82 billion and $85 billion, up from $80 billion to $83 billion previously. Similarly, adjusted earnings for the year are now projected at $35.50 to $37.00 per share, up from the previous guidance of $33.50 to $35.00 per share.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Blue Chip Dividend Stocks to Buy Now and 10 Best Fortune 500 Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.